Life Sciences Archive » August, 2021

Life Sciences - August, 2021

325 articles

• Anti-Holmes Bias, Abuse Focus In 1st Day Of Jury Selection
• Endo Unit Loses Trial To Stop Launch Of Vasostrict Generic
• Anda's Opioid Sales Were In DEA's 'Bull's-Eye,' Jury Is Told
• Fed. Circ. Mulls Undoing Mylan Loss On Inhaler IP Validity
• What The Nondebtor Release Bill Means For Chapter 11 Filings
• USPTO Request Shows Need For Patent Eligibility Reform
• Tufts Settles Claim It Punished Student For Bogus-Data Report
• 3 Firms Guide Ashland's $1.65B Adhesives Biz Sale
• Law360 MVP Awards Go To 182 Attys From 77 Firms
• Breaking IP Barriers: Q&A With Cadwalader's Dorothy Auth
• What The Judiciary's Font Recommendations Can Teach Us
• Patent Prosecution Pro From Baker Botts Joins MoFo
• Vaccines, Tuition, Race: The Litigation On Law Schools' Radar
• How Firms Can Help Law Schools Leap Into The Future
• Meet The Lawyers On Deck At The Elizabeth Holmes Trial
• 4 Ideas For Updating Law Schools Post-Pandemic
• Gov't Contracts Of The Month: Vaccine, IT, Disinformation
• Holmes' Mental State Key To Fraud Defense, Legal Pros Say
• Holmes' Health Docs Allege Balwani Abused, Controlled Her
• Jury Awards $4.7M In Mass. General Genetic Test Patent Trial
• McGuireWoods Sues Men's Health Co. For Unpaid Atty Fees
• US v. Elizabeth Holmes: The Case Against Theranos' Ex-CEO
• 6th Circ. Says Medical Cos. Can't Arbitrate Trade Secrets Row
• Media Co. Says Disability Doesn't Defeat Harassment Story
• Complete Genomics Gets Trim Of Illumina's DNA Tech IP Suit
• Chinese Cos.' US IPOs Plunge Amid Regulatory Crackdowns
• Cannabis Bill Roundup: NC Inches Closer To Medical Pot
• Ex-Pharma Co. Heads Plead Guilty In Trade Secrets Case
• New Shadow Trading Enforcement Lessons For Private Funds
• Commerce Sets Early Duties On Indian, Russian Polymer
• UMass Students Lose Bid To End School Vaccine Mandate
• Ex-Theranos CEO Elizabeth Holmes' Top 5 Pretrial Battles
• Goodwin Continues Expansion Of Private Equity Group
• Sacklers Agree To Forgo Non-Opioid Ch. 11 Releases
• Rite Aid Strikes Deal To Avert Opioid MDL's 1st Pharmacy Trial
• Fed. Circ. Forecast: Apple Fights Caltech's $1.1B Patent Win
• Elizabeth Holmes Mental Health Docs May Be Unsealed Soon
• J&J Won't Be Barred From 'Texas Two-Step' In Delaware Court
• FDA Denies Marketing Applications For 55,000 E-Cig Products
• GSK Arbitration Bid Axed In Consultants' Prison Stint Suit
• SEC Seeks Early Win In Insider Trade Suit Against HK Couple
• 2nd Circ. Won't Rehear FTC's 1-800 Contacts Loss
• USTR Mulls New China Tariff Reprieve Amid Delta Virus Threat
• Ga. Justices Question Judge's Immunity Grant To Court Clerks
• Zydus To Appeal Takeda's Antitrust Win In Drug Patent Row
• Ky. High Court Sinks Suit Over Kidney Transplant Trial
• Litigation Injunctions Extended In Mallinckrodt Ch. 11
• Stem Cell Clinic Says Ga. Lacks Authority To Bring $6.4M Suit
• Students Say Vax Mandate Not Like Top Court Smallpox Case
• Chancery Tosses Class Suit Over $3B Zimmer Biomet Cashout
• Fed. Circ. Wipes Out $1.1B Juno IP Win On Cancer Drug
• Ropes & Gray-Advised Neurogastrx Closes $60M Series B
• 1st Circ. Backs Insys Execs' Convictions, Jury Findings
• 'Sword Of Damocles' Over Endo In Opioid Trial, Judge Says
• Purdue Ch. 11 Judge Says Sackler Releases Should Be Tighter
• Pentagon Says Service Members Must Get COVID Vax ASAP
• CytRx Investor Seeks Records To Investigate Share Increase
• Trustee Tells High Court Not To Review Revived $31M Suit
• J&J's Talc Denials Merit Punitive Damages, Calif. Jury Is Told
• Mallinckrodt Says Letting Injunctions End Puts Ch. 11 At Risk
• Theranos Judge Cuts Potential Jurors For Anti-Holmes Bias
• US Is Urged To Oppose Brazil's Vaccine IP Waiver Bill
• Takeda Can't Duck Generic-Drug Delay Suit At 2nd Circ.
• Grassley Amendments Are Not The Way To Reform The FCA
• Golf Instructor Urges 11th Circ. To Revive Lialda Lawsuit
• 6th Circ. Revives Suit Over J&J Unit's Pelvic Mesh
• CytoDyn Dissidents Sue In Chancery Over Board Proxy Fight
• CBC-Led Group To Buy Stake In $2.5B Korean Botox Co.
• Calif. Jury Clears C.R. Bard Over Design Of Vein Filter Implant
• FTC, Illumina Clash On Merger's Potential To Win Cancer War
• QVC, Suzanne Somers Can't Stop Dispute From Going To Trial
• Avenatti Gains Edge As Feds Show Hand In Mistrial
• Green Card Applicants Must Be Fully Vaxxed Against Virus
• Jones Day Easily Beats Ferring's $1M Trial Sanctions Motion
• Glenmark Still Fighting To End DOJ Interviews Of India Execs
• J&J Must Face Ill. Pelvic Mesh Suit, 7th Circ. Says
• Zantac Makers, Retailers Urge Nix Of Medical Monitoring Class
• Esperion Class Attys Nab $6M In Fees From $18M Settlement
• AbbVie's Humira Patent Claims Survive Dismissal Bid
• Navigating Asia-Pacific Health M&A In The Wake Of COVID
• Talc Users Seek Court Order To Bar J&J Liability Spinoff
• Imerys Gets OK For $6.2M Ch. 11 Property Acquisitions
• 2 Firms Seek $1.5M For COVID-19 Vax Developer Suit In Del.
• Kirkland-Led Fashion Platform Joins Wave Of IPO Filings
• Epstein Becker Adds Life Sciences Pro From Ogletree
• How The 'Rocket Docket' Continues To Roar Through COVID
• FibroGen Gets 1 Anemia Patent Revived On Appeal
• No More Speeches, Settle This Ch. 11, Purdue Judge Urges
• Fed. Circ. Cuts More Claims In J&J Robotic Surgery Patent
• Zetia Drug Buyers Win Class Cert. Against Merck, Glenmark
• California Jury Awards $26.5M In Talc Mesothelioma Trial
• Optometry Chain Wants Out Of Consumers' Robocall Suit
• DLA Piper Seeks $350K For Tyrogenex Suit Deal In Chancery
• 4 Firms Rep As Pfizer Buys Cancer Drug Co. In $2.3B Deal
• Pfizer Gets Full FDA Approval Of COVID-19 Vaccine
• J&J Backs MDL For Sunscreen Carcinogen Suits
• Generics Group Says 'Skinny Label' Suit Should Not Proceed
• Holmes Can't Stop Ex-Theranos Lab Director From Testifying
• Meet The Top Attys Battling McKinsey In New Opioid MDL
• NJ Joins $26B Opioid Settlement With J&J, Pharma Cos.
• Regeneron Wants COVID-19 Tech Patent Suit Axed
• USDA's Animal Protection Failures Show Change Is Needed
• Bristol-Myers Unit Settles Over Generic Cancer Drug
• EU Targets Illumina's Completion Of Grail Deal Amid Probe
• Abbott Labs Can't Escape Claims Baby Formula Killed Infant
• Health Hires: Goodwin, Decibel Therapeutics
• NY Decries 'Brazen Gaslighting' By Endo's Opioid Attys
• Judge Urges Attention To Individual Stories In Purdue Ch. 11
• Feds Accuse Pharma Co. Manager's Wife Of Insider Trading
• AbbVie, Janssen Win IP Fight Over Cancer Drug Imbruvica
• IP Forecast: Ferring Seeks Sanctions Against Jones Day
• NJ Pot Regulator Adopts First Rules For Adult-Use Market
• Lexington Insurance Wants Out Of BCBS Antitrust Coverage
• Maslon Names New Co-Chair Of Firm's Litigation Practice
• SmileDirect Settles Case Over Alabama Dental Board Rules
• What China's Patent Linkage System Means For US Drug Cos.
• SEC Sues Ohio Company Over COVID-19 Product Claims
• Why A Missed Email Could Cost You Your Case
• Bill Would Shift $9.6B From DOD To Global Vaccine Effort
• 1-800 Contacts Sues Warby Parker Over Search Engine Ads
• Illumina Completes $7.1B Grail Deal Amid Antitrust Scrutiny
• Roundup MDL Judge Prods Monsanto To Settle Cases Earlier
• SEC's 'Shadow Trading' Suit Dives Into Murky Area Of Law
• Grocery Chain Wants Out Of Ohio Counties' Opioid Bellwether
• Fed. Circ. Won't Revive NuVasive Surgery Patent Claims
• Teva Wants Eli Lilly Sanctioned In Migraine Drug Patent Fight
• Perrigo Rebuts Investors, Court Over Tax Accounting Rule
• Shareholders Sue Biopharma Co. Over Alzheimer's Drug Trials
• Lessons From Indiana University Vax Mandate Case
• Smith & Nephew Owes Nothing In Hip Resurfacing Device Trial
• Ex-Purdue Chair Denies Blame For Opioid Crisis
• Pfizer Gets PTAB To Review Neulasta Patent In Amgen IP Row
• Judge Lets Most Of Xyrem Antitrust Suit Against Jazz Survive
• 'No End In Sight' As Endo, Arnold & Porter Reveal Opioid Files
• End-Payors Again Denied Cert. In Niaspan Pay-For-Delay MDL
• Fed. Circ. OKs Alice Ax Of SmileDirectClub Patent
• Okla. Seed-To-Sale Challenge Is Moved To Different Court
• Sacklers Say They'll Fight Any Attempt To Foil Ch. 11 Releases
• Couple Wants Early Win In SEC's Insider Trading Suit
• GMU Law Prof Gets Exemption After Challenging Vax Mandate
• 8th Circ. Leaves 3M Surgical Warming Device Verdict In Place
• SEC Sues Exec For Trading On 2016 Pfizer Merger News
• Actavis Drug Didn't Cause Man's Heart Attack, Jury Finds
• DOJ Defends Glenmark, Teva Executive Interviews Abroad
• UMass Says Students Can't Block COVID-19 Vaccine Mandate
• Arthrex Asks USPTO Director To Review 2017 PTAB Decision
• Genus, Lannett Reach Deal To End Suit Over Cocaine Drug
• Chancery Dismisses Challenge To $2.8B Genomic Health Sale
• These Law Firms Have The Most Diverse Equity Partnerships
• Robbins, Friedlander Seek To Lead $1.8B Biotech Sale Suit
• Fed. Circ. Axes Teva Antibody IP But Allows Treatment Patents
• Biotech Says Celgene-BMS Deal Threatens Drug Development
• Rutgers Students Ask Court To Block COVID Vaccine Mandate
• Witness's COVID-19 Diagnosis Delays CR Bard Implant Trial
• Sackler Reps Say They Can't Sell Assets Without Releases
• J&J's Talc Indifference Led To Woman's Cancer, Jury Hears
• Monsanto Seeks High Court Input On $25M Roundup Verdict
• Montana Hit With Suit Over Abortion Restriction Laws
• Greenberg Boosts Medical Device Practice With Maslon Attys
• Ex-Theranos CEO Holmes Wants To Go Maskless During Trial
• Judge Lets Dana-Farber Advance Cancer Drug IP Suit
• Trulieve Workers, Applicants Nab Class Cert. In Hiring Dispute
• Ex-California Mayor Charged With Taking Pot Industry Bribes
• 8th Circ. Restores 3M Warming Device MDL
• Law360's Diversity Snapshot: What You Need To Know
• Jim Bakker Loses Fight to Block COVID 'Cure' Investigation
• Fed. Circ. Backs Teva In Cancer Drug IP Row With Generics
• Sacklers' Ch. 11 Releases Are Fair, Supporting States Say
• Boston Scientific Beats FCA Suit Over Defective Defibrillators
• Ohio Counties Don't Want 'Legal Opioid' Talk In Bellwether
• Fed. Circ. Partly Revives Challenge To Medline Catheter IP
• DOJ Denies 'Rewriting' Price-Fix Indictment of Glenmark, Teva
• Drug Benefit Managers Call Feds' Price Disclosure Rule Faulty
• High Court Asked To Strike Down Bankrupt Lab's $31M Suit
• Kilpatrick Helps With $125M Manhattan Office Loan
• Pa. Judge Clears Kratom Death Case For Trial
• Greenberg, Foley Steer $1B Surgical Robotics SPAC Merger
• 5 Reasons Lawyers Often Fail To Secure Litigation Funding
• Actavis Wants A Win In Testosterone Heart Attack Suit
• 'Flanax' Trademark Fight Heading To High Court Again
• UK Litigation Roundup: Here's What You Missed In London
• Covington Atty 'Really Angry' After DOJ Alleges FCA Mischief
• At Opioid Trial, NY's Lead Atty Says Neighbor OD'd Last Week
• Lannett Investors Nab Cert. In Suit Over Price-Fix Probes
• Mylan Latest To Urge Justices To End PTAB's Fintiv Rule
• Purdue's Ch. 11 Trial Opens With Attacks On Sackler Releases
• Supreme Court Declines To Block Indiana Univ. Vax Mandate
• Despite Giuliani's Assertion, Lawyers Cannot 'Throw A Fake'
• Brazil's Senate Passes COVID Vaccines License-Waiver Bill
• 10% Of AIA Petitions Have Been For Pharma, Biologic Patents
• Hemp Group Says FDA Inaction On CBD Harms Consumers
• The Complexity Of COVID-19 Price-Gouging Compliance
• IP Forecast: Activision Eyes Axing Patents Before Texas Trial
• Albright Slams 'Blatant Forum Shopping' In SmileDirect Case
• InterMune, Roche Sue For Millions Paid In Ex-CEO's Defense
• It's Time To Upgrade Our Attorney Licensure Rules
• Biden Wants Congress To Set Sights On Cutting Drug Prices
• Claims Filed Too Late In Cook Medical Vein Filter Suit
• Endo 'Head Shot' Penalty Mulled In Opioid Discovery Fight
• FDA Bars Charlotte's Web CBD As Dietary Supplement
• Chancery Orders Injunction Hearing On CytRx Vote Coercion
• Roche Can't Ax Ravgen's DNA Tech Patent Suit, Judge Finds
• Former Univar Exec Seeks Quick Win In $850K Severance Suit
• 11th Circ. Won't Scrub 'Pill Mill' Nurse's Convictions
• Elite Trainer Jorge Navarro Cops To Racehorse Doping
• Mallinckrodt Asks For Another 3-Month Hold On Product Suits
• Considering Short- And Long-Term Effects Of COVID IP Waiver
• Endo Cases Highlight Rare Default Risk In Discovery Failures
• Hiscox Needn't Defend Med Co. In $6.4M False Ad Suit
• Telehealth Exec Hit With New Charges In $784M Fraud Case
• Data-Based Predictions On Case Timelines After Pandemic
• Novartis Blood Cancer Drug Suits Centralized In Florida
• 'This Cannot Go On': Opioid Trial Turmoil Intensifies In NY
• 2nd Circ. Nixes Vitamin C Price-Fixing Case, Again
• Congress' Bankruptcy Bills May Be Too Clumsy To Work
• No MDL For Weight Loss Carcinogen Cases, JPML Says
• Foley Hoag, Latham Lead RNA Tech Co.'s $1.2B SPAC Merger
• Senate Infrastructure Bill Inches Forward Pot Research Efforts
• Life Sci Cos. Should Prep For Enforcement After COVID Pause
• Cooley-Led Eliem Therapeutics Prices $80M IPO
• Ex-Theranos CEO Must Unseal Mental Health Docs
• Embracing ESG
• Benzene In Sunscreens Could Be The Next Big Toxic Tort
• Pa. Judge Rejects QVC Privilege Bid In Suzanne Somers Suit
• $16M Deal Over Baxter Forex Controls Gets Final OK
• Shire Pays $1.9M, Boosting ADHD Med Antitrust Deal To $3M
• Calif. Panel Affirms $87M Roundup Award Against Monsanto
• GSK Redo Doesn't Cure Generics' 'Skinny Label' Uncertainty
• Glenmark, Teva Say DOJ 'Rewriting' Price-Fixing Indictment
• Arnold & Porter Atty Opioid Trial Remarks 'Crazy,' Court Told
• The IPO Market Is Finally Taking A Breather
• Defense Secretary Wants Mandatory COVID Vax For Military
• FTC Wants More Info On AbbVie's $550M Device Deal
• Claims Court Bars VA Medical Supply Deal Transfer To DOD
• Biden To Scrap Trump's Most-Favored Nation Drug Pricing
• Ex-HHS Official Inks Deal On Virus Whistleblower Claims
• UK Takeover Panel Sets Auction For £1B Inhaler Co. Vectura
• 7th Circ. Backs Spinal Device Co. In Trade Secrets Fight
• FTC Asks 2nd Circ. To Rethink 'Free Pass' For 1-800 Contacts
• Walgreens Faces Skeptical 9th Circ. In Theranos Cert. Fight
• Kirkland Reps Hines On $750M Commercial Real Estate Fund
• Zimmer Hip Implant Suit Tossed Over Expert Opinion
• Purdue Allotted 10 Days For Ch. 11 Confirmation Trial
• Cannabis Co. Wants Out Of Utah Medical Pot Licenses Suit
• Retention Is Key To Meaningful Diversity At Law Firms
• Atty Fees Capped At 15% In $26B Opioid MDL Settlement
• 5 Highlights As Endo, Arnold & Porter Face Opioid Oblivion
• J&J Talc Case Sent Back To Philly After 11th-Hour Removal
• $26B Opioid Deal Sparks 'Turf Wars' From Local Governments
• Holmes Wants Ex-Theranos Lab Director Excluded From Trial
• Federal Cannabis Reform: Inevitable But Inevitably Piecemeal
• Health Hires: Robinson & Cole, Benesch Friedlander
• Taxation With Representation: Hogan Lovells, Baker McKenzie
• UK Inhaler Maker Spurns Philip Morris For £958M PE Takeover
• Valeant To Pay $23M To End 'Secret' Pharmacy RICO Claims
• AstraZeneca Asks Judge To Bar Use Of Fintiv Rule In PGRs
• Justices Asked To Hear Fight Over Indiana Univ. Vax Mandate
• Purdue Pharma Says Sackler Releases Are Vital To Ch. 11 Plan
• Baker Botts Snaps Up Ex-Simpson Thacher Atty In Houston
• Pa. Justices Take Up 3rd Circ. Case Over Device Liability
• Biopharma Co. Adagio Grabs $309M In Cooley-Led IPO
• EQRx Worth $3.65B In Deal Led By Goodwin, White & Case
• LA Courts Will Require Workers To Be Vaxxed After FDA's OK
• Endo Calls Out Fiery 'Rhetoric' In NY Opioid Trial
• $235M GSK Win Stays, But Fed. Circ. Tells Generics To Relax
• Polsinelli Trims But Can't Beat Pharma Co.'s Malpractice Suit
• Actavis Marketed Testosterone Drug Off-Label, Ill. Jury Told
• 2 Wins For AI-Made Inventions May Be Just The Beginning
• CIT Backs Anti-Dumping Duties Against Chinese Chlorine Cos.
• Tenn. 48-Hour Abortion Waiting Period Is Valid, 6th Circ. Says
• FDA Med Conference Study Raises Pharma Enforcement Risks
• DOJ Denies Doing End-Run Around FCA Intervention Denial
• Biotech Board Chair Ran $2.2M Penny Stock Fraud, Feds Say
• IP Case Management Takeaways 18 Months Into Pandemic
• Baker McKenzie, Cooley Build $2B Bayer-Vividion Deal
• 8th Circ. Backs 3M In Nixing Suit Over Warming Device
• Teva Piles Onto Strong-Arm Tactic Accusations Against DOJ
• Arnold & Porter Fights 'Extreme Sanctions' In NY Opioid Trial
• Odonate Therapeutics Can't Beat Investor Suit Over Drug Trial
• C.R. Bard Implant Called 'Ticking Time Bomb' At Trial Open
• WilmerHale Attys Helped Lose Theranos Data, Judge Says
• Endo Exec Ripped FDA 'Window Dressing,' Jury Hears
• 2 Firms Seek To Lead GW Pharma Suit Over $7.2B Deal
• Trade Groups Urge Justices To Hear NY Opioid Tax Challenge
• Unvaxxed George Mason Law Prof Challenges COVID Policy
• Patent Pro Moves From Mintz Levin To Greenberg Traurig
• How Citizen Petitions Influence FDA Drug Approvals
• Zetia Judge Must Rethink 'Faulty' Class Cert., 4th Circ. Says
• Avoiding Unauthorized Practice Of Law In Remote Work
• Considerations For Patent Assignments After Minerva Ruling
• Drug Price Checker Replies To Pharma Group's Counterclaims
• Abbott Sues To Invalidate Rival's Diabetes Tech Patents
• Endo Discovery Fight Overshadows NY Opioid Trial
• Rite Aid's 11th-Hour Axing From Pa. Talc Case Troubles Judge
• Hikma Should Face Amarin's Patent Suit, Magistrate Says
• NY Veterinarian Cops To Role In Horse Doping Scheme
• FTC Says Illumina Case Too Simple For Extra Experts
• Fed. Circ. Mulls Generics' Invalidity Argument In Teva IP Row
• Philly Is Wrong Venue For Cancer Emissions Suit, Court Says
• Glenmark Accuses DOJ Of 'Strong-Arm Tactics'
• Mallinckrodt Ch. 11 Creditor Blasts Proposed Payout Plan
• PE Settlement Illustrates New FCA Liability Theories In Play
• Enviros Seek Ban On Live Birds, Mammals Trade
• Firms Seek Fees For Biogen's 'Egregious' Tactics In Docs Suit
• Striking The Right Academic Research Deal As A Sponsor
• Biomet Fails To Escape Mo. Jury's $21M Hip Implant Verdict
• Trevena Settles Opioid Substitute Stock-Drop Suit For $8.5M
• 3 Firms Vie To Lead Investor Suit Against Mass. Biotech Co.
• Takeda Kept Generic Drug Off Shelves For 6 Years, Suit Says
• Weil, Paul Weiss Craft Sanofi's $3.2B Deal For Translate Bio
• Latham Nabs Ex-Skadden Partner As IP Litigation Vice Chair
• Teva's Opioid Order Monitoring On Hot Seat In NY Trial
• Indiana Univ. Can Keep COVID Vax Mandate During Appeal
• The Non-Tech Antitrust Conduct Cases Defining 2021
• Impax Inks $33M Deal With Investors In Price-Fixing Suit
• Wachtell-Led Immunovant Lands $200M From Top Shareholder
• Haynes And Boone Adds Health Care Pro From DLA Piper
• NY Judge Rips Endo On Lagging Discovery In Opioid Trial
• Del. Judge OKs Avadim's $70M Ch. 11 Debt Takeback Sale
• PTAB Axes Patent Claims For Nektar Hemophilia Drug
• WSJ Publisher Asks To Unseal Elizabeth Holmes Docs
• Cooley-Led Adagio Plots Course For $301M IPO
• UMass Students Sue To Block School's Vaccine Mandate
• Sanofi Taps Novartis GC For New Top Attorney Spot
• Research Org Can't Duck Suit Over Unsolicited Faxes